2015 News Releases

Webcast ImageWebcast
Neuralstem, Inc at BIO CEO & Investor Conference (Replay)
02/13/17 at 8:30 a.m. ET
Webcast ImageWebcast
Neuralstem, Inc. at 29th Annual ROTH Conference (Replay)
03/13/17 at 12:00 p.m. PT
Webcast ImageWebcast
Neuralstem, Inc. at Oppenheimer 27th Annual Healthcare Conference (Replay)
03/21/17 at 1:00 p.m. ET
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
12/09/15Neuralstem Reports Third Quarter 2015 Financial Results
Adds Depth to Management Team with Appointment of Industry Veterans as Second Asset Advances towards Phase 2 GERMANTOWN, Md., Nov. 9, 2015 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR) a biopharmaceutical company leveraging its unique human neural stem cell-derived platform to identify and develop novel neurogenic therapies for diseases of the central nervous system (CNS), today reported its financial results and business update for the three and nine months ended September 30, 2015. Ne... 
Download PDFPrinter Friendly Version
12/08/15Data for Neuralstem's Novel NSI-189 Molecule in Major Depressive Disorder Published in Molecular Psychiatry
Phase 1b Data Demonstrate Potential of Oral Neurogenesis-based Therapies GERMANTOWN, Md., Dec. 8, 2015 /PRNewswire/ -- Neuralstem, Inc. (NASDAQ: CUR) today announced the publication of Phase 1b data in Molecular Psychiatry for their lead small molecule drug, NSI-189, in patients with major depressive disorder (MDD). Neuralstem is a biopharmaceutical company developing treatments for central nervous system diseases based on its proprietary neural stem cell platform. The report showed that NSI-18... 
Download PDFPrinter Friendly Version
09/29/15Neuralstem Investigator Provides Phase II Update on ALS Cell Therapy at American Neurological Association Annual Meeting
GERMANTOWN, Md., Sept. 29, 2015 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that nine-month Phase II and combined Phase I and Phase II data on the NSI-566 trial in amyotrophic lateral sclerosis (ALS) was presented at the American Neurological Association Annual Meeting by principal investigator, Eva Feldman, MD, PhD, Dire... 
Download PDFPrinter Friendly Version
09/24/15Neuralstem Investigator to Provide Update on ALS and Alzheimer's at American Neurological Association Annual Meeting
GERMANTOWN, Md., Sept. 24, 2015 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that principal investigator, Eva Feldman, MD, PhD, will give an update on NSI-566 Phase I and Phase II trial data in amyotrophic lateral sclerosis (ALS) at the American Neurological Association Annual Meeting in Chicago, Il on Monday, September 28... 
Download PDFPrinter Friendly Version
08/10/15Neuralstem Reports Second Quarter 2015 Financial Results
GERMANTOWN, Md., Aug. 10, 2015 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR) a biopharmaceutical company developing neural stem cell-derived small molecule and cell therapy treatments for central nervous system diseases, reported its financial results and business update for the three and six months ended June 30, 2015. Neurogenic Small Molecule Program NSI-189 Phase II in Major Depressive Disease (MDD): Neuralstem is developing regulatory and clinical plans for a multicenter, Phase II c... 
Download PDFPrinter Friendly Version
07/23/15US District Court Rules In Favor Of Neuralstem In Patent Infringement Case
GERMANTOWN, Md., July 23, 2015 /PRNewswire/ -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the U.S. District Court for the District of Maryland dismissed StemCells, Inc.'s patent infringement case with prejudice in StemCells, Inc. v. Neuralstem, Inc. in favor of Neuralstem, on July 22, 2015.The District Court held a bench trial on the is... 
Download PDFPrinter Friendly Version
06/29/15Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market
GERMANTOWN, Md., June 29, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced today that it has been approved for listing on the NASDAQ Capital Market under the symbol "CUR." The Company's common stock will continue to trade on the NYSE MKT until the market close on July 10, 2015. Trading on the NASDAQ Capital Market is expecte... 
Download PDFPrinter Friendly Version
06/26/15Preclinical Data On Neuralstem's Genetically Modified HK532-IGF-1 Stem Cells In Alzheimer's Disease Presented At International Society For Stem Cell Research Annual Meeting
GERMANTOWN, Md., June 26, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden http://neuralstem.com/publi... 
Download PDFPrinter Friendly Version
05/08/15Neuralstem Reports First Quarter 2015 Financial Results And Provides Business and Clinical Update
GERMANTOWN, M.D., May 8, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, reported its financial results for the three months ended March 31, 2015 and provided a business and clinical update. "Neuralstem made substantial clinical progress this quarter in both our cell therapy and small molecule programs. We announced positive top-lin... 
Download PDFPrinter Friendly Version
05/06/15Neuralstem Appoints Jonathan Lloyd Jones as Chief Financial Officer - See more at: http://investor.neuralstem.com/press-releases?year=2015#sthash.ykRlRzw1.dpuf
GERMANTOWN, Md., May 6, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR), a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced the appointment of Jonathan Lloyd Jones to the position of Chief Financial Officer, effective May 18th. Mr. Lloyd Jones brings to the position more than 25 years of corporate finance and business development experience.   Most recently, Mr.... 
Download PDFPrinter Friendly Version
03/16/15Neuralstem Reports Fiscal 2014 Fourth Quarter Financial And Year-End Business Results
GERMANTOWN, Md., March 16, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) (the "Company" or "Neuralstem") today reported its financial results for the fourth quarter and year ended December 31, 2014. "Neuralstem has progressed into a clinical development stage company focused on the central nervous system (CNS)," said Richard Garr, Neuralstem President and CEO. "During 2014 we added two established industry leaders as Independent Directors, Catherine Angell Sohn, Pharm.D. and Sandford Dr... 
Download PDFPrinter Friendly Version
03/12/15Neuralstem Announces Topline Results Of Phase II ALS Trial
GERMANTOWN, Md., March 12, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated. Secondary efficacy endpoints at nine months post-surgery indicate a 47% response rate to the stem cell ... 
Download PDFPrinter Friendly Version
03/04/15Neuralstem To Present At Barclays Global Healthcare Conference 2015
GERMANTOWN, Md., March 4, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Richard Garr, President and CEO, will present at the Barclays Global Healthcare Conference 2015 on Thursday, March 12, at 2:35 p.m. EDT in Miami. An audio webcast of the presentation will be broadcast simultaneously through the Investor Center home page of Neuralstem's website: investor.neuralstem.com. An archive of the presentation will also be available for 30 days. About Neuralstem Neurals... 
Download PDFPrinter Friendly Version
02/03/15Neuralstem to Present at BIO CEO & Investor Conference 2015
GERMANTOWN, Md., Feb. 3, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that Richard Garr, President and CEO, will present at the 17th Annual BIO CEO & Investor Conference on Monday, February 9, at 3:30 p.m. EST at the Waldorf Astoria in New York City. A live audio webcast of the presentation will be available by visiting the Investor Center home page of Neuralstem's website: investor.neuralstem.com. An archive of the presentation will be available for 30 days. About... 
Download PDFPrinter Friendly Version
01/06/15Neuralstem To Present At Biotech Showcase 2015
GERMANTOWN, Md., Jan. 6, 2015 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the Company will present at the seventh annual Biotech Showcase in San Francisco on Tuesday, January 13, at 9:00 a.m. PST. Richard Garr, President and CEO, will present an overview on the company's clinical advancements of 2014 for both the cell therapy and small molecule drug discovery pipeline platforms. This will include the status of the company's lead cell therapy asset, NSI-566 for amyotrophi... 
Download PDFPrinter Friendly Version